Skip to content

NewAmsterdam Pharma Company N.V.

NAMS NAMSW

CIK 0001936258

← back to feed
Revenue (TTM)
$25.51M
−50.6% YoY Q1 Apr 2026
Net Income (TTM)
−$177.34M
+15.6% YoY Q1 Apr 2026
EPS Diluted (TTM)
−$1.50
+32.8% YoY Q1 Apr 2026
Gross Margin
—
Q1 Apr 2026
Operating Margin
-855.0%
Q1 Apr 2026
Net Margin
-695.1%
Q1 Apr 2026
Free Cash Flow (TTM)
−$153.98M
Q1 Apr 2026
Cash
$457.61M
Q1 Apr 2026
Total Debt
—
Q1 Apr 2026
Shares Outstanding
116.9M sh
Q1 Apr 2026

Revenue & Net Income

EPS (Diluted)

Margins

Cash Flow

Revenue Growth (YoY)

Balance Sheet

Cash vs Debt

Recent filings